key: cord-0765086-5xo340xd
authors: Huang, Qingrui; Yan, Jinghua
title: SARS-CoV-2 virus: vaccines in development
date: 2021-01-22
journal: nan
DOI: 10.1016/j.fmre.2021.01.009
sha: ae445235e8eb1c760f013b747dd5645d490fd1e2
doc_id: 765086
cord_uid: 5xo340xd

The ongoing COVID-19 pandemic, caused by SARS-CoV-2, is an unprecedented challenge to humanity. Global herd immunity may be necessary before resumption of normal economic and societal activities. Since the beginning of the outbreak, the development of COVID-19 vaccines has proceeded at record speed using nearly all available platforms or strategies to maximize vaccine success. A total of 42 vaccine candidates have now entered clinical trials and encouraging data from several vaccine candidates in phase 1 or 2 clinical trials have been reported. In this review, we examine current COVID-19 vaccine candidates, discuss their strengths and weaknesses, summarize published clinical data and analyze future challenges.

. Similar to other human coronaviruses such as SARS-CoV, 61 SARS-CoV-2 uses an S protein for entry into host cells [47] [48] [49] . The S protein can be 62 functionally categorized into S1 and S2 subunits, which are separated by a protease 63 cleavage site [48, 50, 51] . First, the receptor-binding domain (RBD) at the C terminus 64 of the S1 subunit engages human angiotensin-converting enzyme 2 (hACE2) as the such as low temperature or rational gene modifications involving codon 89 de-optimization and deletion of certain genes associated with replication or eluding 90 human immune recognition [64, 65] . An advantage of such vaccines is that they mimic 91 natural infections and can stimulate potent cellular response aside of induction of 92 virus neutralizing antibodies. The disadvantage to these vaccines is the safety concern 93 about virus reverse mutations in vaccinated individuals. To date, only three 99 Purified inactivated vaccines are widely used for prevention of diseases caused by 100 viruses such as the influenza virus and the poliovirus [66] [67] [68] . Selection for a seed 101 virus strain, characterized by highly efficient proliferation and high genetic stability, 102 is the first step for developing SARS-CoV-2 inactivated vaccines. The selected strain 103 is then propagated in cell cultures, usually vero cells followed by inactivation using 104 chemicals such as β-propiolactone. After optimized purification steps including 105 chromatography, pure inactivated vaccine preparations are obtained. Because of the 106 whole virus being presented to the immune system, an advantage of inactivated 107 vaccines is that the elicited immune response will target not only the S antigen but 108 also other structural or non-structural proteins including the M, E and N proteins. The with internals of 3 or 4 weeks achieved higher neutralizing antibody titers than the (Table 1) .

Of these, NVX-CoV2373 (developed by Novavax) is a recombinant nanoparticle (Table 1) . (Table 1) .

A phase 1/2, single-blind, randomized controlled trial of S-encoding ChAdOx1 phase 2 trial in 508 adults (aged 18 and older) was also reported (NCT04341389) [37] .

In the phase 2 trial two doses were tested, 5x10 9 and 1x10 11 virus particles, each as 246 one shot. Results showed that 9% of participants in the high-dose group and 1% in the 247 low-dose group reported grade 3 adverse reactions (mostly fever). This indicated that 248 the vaccine was relatively reactogenic, especially when delivered at a high dose. (Table 1) . Several other mRNA vaccine candidates including one 267 developed by CurVac and one by the Chinese Liberation Army are also in phase 1 or 268 2 clinical trials (Table 1 ). However, given that there has been no previous mRNA 

Jinghua Yan, a professor and Principle Investigator in Institute of Microbiology

Her reserach interest mainly 616 focuses on the development of vaccines and therapeutic antibodies against emerging